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Biologic valve re-replacement was examined in a series of 1343 patients who 
underwent aortic valve replacement at The Prince Charles Hospital, 
Brisbane, with a cryopreserved or 4 ° C stored allograft valve or a xenograft 
valve. A parametric model approach was used to simultaneously model the 
competing risks of death without re-replacement and re-replacement before 
death. One hundred eleven patients underwent a first re-replacement for a 
variety of reasons (69 patients with xenograft valves, 28 patients with 4 ° C 
stored allograft valves, and 14 patients with cryopreserved allograft V lves). 
By multivariable analysis younger age at operation was associated with 
xenograft, 4°C stored allograft, and cryopreserved allograft valve re- 
replacement. However, this effect was examined in the context of longer 
survival of younger patients, which increases their exposure to the risk of 
re-replacement as compared with that in older patients whose decreased 
survival reduced their probability of requiring valve re-replacement. In 
patients older than 60 years at the time of aortic Valve replacement, the 
probability of re-replacement (for any reason) before death was similar for 
xenografts and cryopreserved allograft valves but higher for 4 ° C stored 
valves. However, in patients younger than 60 years, th e probability of 
re-replacement at any time during the remainder of the life of the patient 
was lower with the cryopreserved allograft valve compared with the 
xenograft valve and 4°C stored allografts. (J Thorac Cardiovasc Surg 
1997;113:311-8) 
B iologic valve replacement devices (xenograft and allograft valves) have an important and comple- 
mentary role in conjunction with mechanical valve 
devices in the treatment of valvular heart disease. 
Freedom from anticoagulant-related hemorrhage 
and a low incidence of thromboembolic events 
remain clear advantages of biologic valves over 
mechanical devices. 1 Furthermore, the allograft 
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valve has an additional advantage over both xeno- 
graft and mechanical valves for aortic valve replace- 
ment in the setting of endocarditis with a lower 
probability of recurrent endocarditis. 2 
However, a clear disadvantage of biologic valves 
is their propensity for failure as a result of leaflet 
degeneration and mechanisms peculiar to allografi 
valves, including geometric distortion and changing 
mechanical properties of leaflets, specifically loss of 
radial extensibility of leaflets, which eventually re- 
sults in central incompetence) 
The usual means of presenting time-related 
events (such as death and re-replacement) after 
valve replacement is by actuarial analysis of single 
events. However, many patients, particularly elderly 
patients, die before a biologic valve requires re- 
replacement. In the setting of competing risks (in 
this context, valve re-replacement before death and 
death before re-replacement), interpretation of the 
Kapian-Meier curve is problematic. 4 In this case, the 
Kaplan-Meier curve for freedom from valve re- 
replacement is conditional that no patient dies 
because the censoring process is used at the time of 
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Table I 
Valve type used at 
primary valve No. of first re- 
replacement N replacements % 
Xenograft 
Carpentier-Edwards* 849 62 7.3 
Hancock? 68 6 8.8 
Xenotech:~ 17 0 0 
Medtronic Intact? 15 1 6.6 
Ionescu-Shiley§ 1 0 0 
Subtotal 950 69 7.3 
Cryopreserved allograft 299 14 4.7 
4 ° C stored allograft 94 28 29.8 
Subtotal 383 42 10.5 
Total 1343 111 8.3 
*Baxter Healthcare Corp., Edwards Division. 
?Medtronic, Inc. 
SMedtronic Heart Valve Division, Irvine, Calif. 
§Mallinckrodt Medical, Inc. 
each death that occurs before re-replacement. Im- 
portant information for the patient and the surgeon 
in deciding between a mechanical or biologic valve 
replacement device is the probability of re-replace- 
ment of a biologic valve before death, which takes 
into account the competing risks of death and 
re-replacement. Grunkemeier and colleagues 5 ap- 
plied a "competing risk" analysis in a group of 
patients undergoing valve replacement with xeno- 
graft prostheses to determine both actuarial valve 
failure (conditional that no patient dies) and actual 
valve failure (probability of failure before death). 
The purpose of this study was to analyze biologic 
valve re-replacement in a series of patients under- 
going aortic valve replacement with cryopreserved 
and 4 ° C stored allograft valves and xen0graft valves. 
The analysis was conducted in the "competing risk" 
domain to depict the unconditional probability (ac- 
tual risk) of valve re-replacement before death after 
aortic valve replacement. The results of this analysis 
may provide information that could improve the 
precision with which a biologic valve replacement 
device and an individual patient are matched. 
Patients and methods 
The purpose of this retrospective observational study 
was to analyze the incidence and time relatedness of 
re-replacement of implanted biologic valves in the aortic 
position. The study group included patients who under- 
went aortic valve replacement (primary and subsequent 
valve replacements) with biologic valves, with or without 
concomitant procedures, at The Prince Charles Hospital 
between January 1, 1970, and January 31, 1990. The 
patient population was obtained from a previously pub- 
lished data set that examined survival after aortic valve 
replacement. 6 Patients who underwent concomitant mi- 
tral valve replacement were not included. Patients who 
received fascia lata and calf heterografts, which are now 
regarded as obsolete because of rapid failure, were not 
included. Patients who Underwent an aortic valve replace- 
ment at another institution but subsequent aortic valve 
replacement at The Prince Charles Hospital were not 
included. 
The study group comprised 1343 patients who under- 
went primary aortic valve replacement, of which 111 
patients ubsequently underwent a first re-replacement of 
the aortic valve prosthesis. Four of these patients under- 
went a second re-replacement but this second re-replace- 
ment was not considered in this analysis. At the initial 
aortic valve replacement, a xenograft valve was used in 
950 patients, a 4 ° C stored allograft valve in 94 patients, 
and a cryopreserved allograft valve in 299 patients (Table 
I). 
Of the 1343 patients who underwent primary aortic 
valve replacement, 1029 were male and 314 were female 
with an age range of 3.2 to 85 years (mean age of 57.3 
years). The mean ages of patients receiving xenografts, 
cryopreserved allografts, and 4°C stored allografts were 
60 years, 51.6 years, and 50 years, respectively. Of the 111 
patients who underwent a first aortic valve re-replace- 
ment, 92 were male and 19 were female with an age range 
of 19 to 80 years (mean age of 53~9 years). 
Operative technique, Aortic valve replacements were 
done with use of the usual methods of cardiopulmonary 
bypass. From 1970 to 1978, myocardial protection was 
provided by continuous coronary perfusion and from 1978 
to 1990, by cold crystalloid cardioplegia with topical 
cooling. 
Xenograft valves were implanted with use of an inter- 
rupted suture technique. Allograft valves were inserted by 
a variety of methods including the sUbcoronary and cylin- 
drical techniques and as an aortic root replacement] 
Xenograft valves were implanted from 1978 to 1990, 4 ° C 
stored allografts from 1969 to 1976, and cryopreserved 
allografts from 1975 to 1990. 
Data collection and follow-up, A number of demo- 
graphic, clinical, pathologic, and surgical variables were 
collected (Appendix A) by study of the patient hospital 
records and from collateral information provided by other 
hospitals and physicians. The data were collected by data 
managers and subsequently checked by the investigators 
before being entered into the database. Re-replacement 
of a previously implanted aortic valve and death were the 
end points of the study. Re-replacement of a valve device 
was undertaken because of leaflet failure caused by de- 
generation (xenografts and allografts) and changing me- 
chanical properties of leaflets (allografts), geometric dis- 
tortion (allografts), replacement valve endocarditis, 
miscellaneous technical reasons, and in the course of 
repair of an ascending aortic dissection. Re-replacement 
of a biologic valve during the repair of an acute or chronic 
ascending aortic dissection despite normal functioning of 
the valve occurred in five patients. One patient, who had 
previously undergone an aortic valve replacement with a 
xenograft valve, underwent cardiac transplantation 9 years 
later. The valve device was censored at the time of the 
transplantation. 
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Table I I  
Reason for re-replacement 
Valve type used at Replacement 
primary valve Leaflet valve 
replacement failure endocarditis Other Total 
Xenograft 53 10 6* 69 
4 ° C stored allograft 24 3 17 28 
Cryopreserved allograft 2 6 65 14 
Total 111 
*Strut obstruction (1), ascending aortic graft infection (1), replacement 
during repair of ascending aortic dissection (4). 
tReplacement during repair of ascending aortic dissection. 
SDehiscence, paravalvular leak, geometric distortion. 
Follow-up information was obtained from hospital 
records and by direct contact with the patient, family, 
cardiologist, and family physician. Follow-up was con- 
ducted through the months of May 1990 to February 1991 
and the closing date for inclusion of events was February 
22, 1991. Only one patient, who underwent aortic valve 
replacement with a xenograft prosthesis, was lost to 
follow-up. The number of patients followed up by time 
interval is outlined in Appendix Table II. 
Data analysis. To estimate the probability of valve 
re-replacement before death, the competing risks of death 
and re-replacement were modeled in the hazard function 
domain. Details are provided in Appendix B. This method 
provides time-related estimates of the proportion of pa- 
tients who will actually have a valve re-replaced. This 
approach can be conceptualized in terms of a cohort of 
patients that is followed up until each patient has either 
had a valve re-replaced or has died before valve re- 
replacement. At any time, one can calculate the propor- 
tion of patients that has had each event or is still free from 
both events. Ultimately, each patient will have one of the 
events and the proportion in each event group will 
become constant. The method also recognizes that the 
final proportion in each event group may well be a 
function of identifiable risk factors. 
The analyses included estimates of the probability of 
re-replacement for any reason (leaflet failure, replace- 
ment valve endocarditis, and technical reasons) for xeno- 
graft valves and 4°C stored and cryopreserved allograft 
valves. Risk factors for re-replacement were sought by 
multivariable analysis using the method of maximum 
likelihood. A nomogram was derived for the relationship 
between probability of re-replacement for any reason 
before death and age at initial aortic valve replacement 
for xenografts and cryopreserved and 4°C stored allo- 
grafts. 
Results 
A first valve re-replacement was done in 69 
patients with a xenograft valve, 28 patients with a 
4°C stored allograft valve, and 14 patients with a 
cryopreserved allograft valve. Valve re-replacement 
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Fig. 1. Nomogram of the time-related proportion of pa- 
tients with xenograft valves (950 patients, 53 re-replace- 
ments) who will actually require valve re-replacement for
any reason before death according to the age of the 
patient. The solid lines are the parametric estimates. 
was done because of leaflet failure, replacement 
valve endocarditis, and a number of other miscella- 
neous causes (Table II). In the multivariable analy- 
sis only younger age at operation was found to be 
associated with increased probability of valve re- 
replacement. 
Xenograft valve re-replacement. Fifty-three pa- 
tients with xenograft valves underwent re-replacement 
for any reason. A nomogram of the time-related 
proportion of patients who will require re-replacement 
for any reason before death, stratified by age at 
operation, is depicted in Fig. 1. The asymptote of each 
curve represents the actual proportion of valves that 
will eventually require re-replacement before the 
death of the patients. 
Re-replacement of 4°C stored allograft valves. 
Twenty-eight patients with 4°C stored allograft 
valves underwent re-replacement for any reason. 
The nomogram of the time-related proportion of 
patients who will require re-replacement for any 
reason before death, stratified by age at operation, is 
depicted in Fig. 2. 
Cryopreserved allograft valve re-replacement. 
Fourteen patients with cryopreserved allograft 
valves underwent re-replacement for any reason. 
The nomogram of the time-related proportion of 
patients who will require re-replacement for any 
reason before death is depicted in Fig. 3. 
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Fig. 2. Nomogram of the time-related proportion of pa- ~ 60 
tients with 4°C stored allograft valves (94 patients, 28 0 00 --80 
re-replacements) who ill actually require valve re-re- 0 5 10 15 
placement for any reason before d ath according to the 
age of the patient. The solid lines are the parametric estimates. 
Age-related re-replacement nomogram. The 
probability of re-replacement for any reason (leaflet 
failure, replacement valve endocarditis, and other 
reasons) before death for xenograft, 4 o C stored, and 
cryopreserved allograft valves by age at operation is 
depicted in Fig. 4. One minus the probability of 
valve re-replacement before death is the probability 
of death before the valve requires re-replacement. 
Discussion 
When a cardiac surgeon a d a patient are consid- 
ering the choice of a valve device, the decision is 
partly influenced by an impression (in the surgeon's 
mind) of the likelihood that an implanted biologic 
valve will require re-replacement before the patient 
dies. This is, of course, particularly relevant in an 
elderly patient in whom, not infrequently, it is said 
that a biologic valve may "outlive" the patient. This 
process, which occurs informally, is taking into 
account in the decision the COmpeting risks of death 
and re-replacement before death. 
The Kaplan-Meier estimate of freedom from re- 
replacement (or other end point such as valve 
degeneration) assumes, because of the censoring 
process, that no patient dies and hence all patients 
will eventually require valve re-replacement. Conse- 
quently, the Kaplan-Meier estimate provides infor- 
mation regarding biologic valve durability and is a 
useful means to compare the durability of valve 
devices inasmuch as death is removed from the 
"3 
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Fig. 3. Nomogram of the time-related proportion of pa- 
tients with cryopreserved allograft valves (299 patients, 14 
reoperations) who will actually require valve re-replace. 
ment for any reason before death according to the age of 
the patient. The solid lines are the parametric estimates. 
computation. Although this is important informa- 
tion, not only for valve manufacturers, but also for 
patients and surgeons, what is of more importance 
to the patient is the probability of requiring a valve 
re-replacement at some time during the remainder 
of his or her life. This information isnot provided by 
the Kaplan-Meier estimate. Because death of the 
patient and re-replacement compete for the valve, 
both end points need to be solved for simulta- neously. 
The analytic tools to deal with multiple nd points 
(competing risks) have been available for a long 
time. Grunkemeier and associates s proposed the 
term actuarial to describe the survivorship function 
(the usual Kaplan-Meier estimate) and the term 
actual risk to describe the competing risk depiction. 
Other terms that have been used to describe the 
actual risk include cumulative incidence funcliorzS 
and cause_specific ailure probability. 9 
The competing risk analysis can be depicted ei- 
ther as the proportion free from re-replacement 
before death or, alternatively, as proportion under- 
going re-replacement before death. In this study, the 
latter depiction was chosen. These curves, particu- 
larly those that portray proportion of patients who 
undergo re-replacement before death, have an un- 
usual shape because they become asymptotic (as 
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Fig. 4. Nomogram of the probability of re-replacement before death for any reason for patients with 
xenograft, 4° C stored, and cryopreserved allograft valves as a function of age at initial valve replacement. 
The solid lines are the parametric estimates. 
time from operation increases, probability of re- 
replacement becomes constant). This is because the 
proportion of patients above the asymptotic part of 
the curve represents those who have died and hence 
the valve devices in those patients are no longer 
available for re-replacement. The competing risk 
plot for xenograft re-replacement (Fig. 1) has a 
clearly defined asymptote compared with the plots 
for 4 ° C stored allograft valve re-replacement (Fig. 
2) and cryopreserved allograft valve replacement 
(Fig. 3). Competing risk is a process of assortment 
into events (in this case death and re-replacement). 
A clear asymptote for xenograft valves occurs at 
approximately 14 years, which means that after this 
time the assorting process has been completed and 
either death or re-replacement has occurred. How- 
ever, there is no asymptote for 4°C stored and 
cryopreserved allograft valves, which indicates that 
the assorting process is still occurring at 15 years 
after operation. The estimates represented in the 
figures do not have ,confidence limits and hence 
carry some uncertainty. 
In the multivariable analysis tudy, younger age at 
operation was found to be a risk factor for re- 
replacement of biologic valves. Previous studies by 
Magilligan and colleagues, I° Jamieson and col- 
leagues, 11 and Gallo, Nistal, and Artinano 12 demon- 
strated that younger age at operation was a risk 
factor for xenograft valve degeneration. Because 
these studies used the Kaplan-Meier estimate, cen- 
soring for death, younger age at operation reflected 
a biologic predisposition to tissue failure at younger 
age. However, in this study, by using a competing 
risk analysis, increased probability of re-replace- 
ment with younger age at operation reflects not only 
a biologic predisposition to leaflet failure, but also 
the fact that younger patients have a lower proba- 
bility of dying than older patients and hence a higher 
probability of eventually requiring re-replacement. 
Similarly, when a competing risk analysis for re- 
replacement is applied to patients with allograft 
valves (4 ° C stored and cryopreserved), the effect of 
younger age at operation on the probability of 
re-replacement reflects the competing risk of death 
and re-replacement, as well as any biologic predis- 
position to leaflet failure. 
The nomogram of the probability of undergoing a
re-replacement sometime during the remainder of the 
patient's life, according to age at operation, is an 
important piece of information for a patient. This is 
depicted in Fig. 4 and provides this probability for 
xenograft, 4° C stored, and cryopreserved allografts. In 
terms of the proportion of patients who undergo 
re-replacement for any reason before death, cryopre- 
served allografts are superior to xenograft valves up 
until the age of approximately 60 years at the time of 
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operation. For a patient 20 years old at the time of 
operation who receives a cryopreserved allograft valve, 
over the remainder of the patient's lifetime there is a 
30% predicted probability that a re-replacement of the 
valve will be required. If this patient were to receive a 
4 ° C stored allograft valve (a valve that is still widely 
used), the predicted probability of a re-replacement 
during the remainder of the patient's life would be 
approximately 50%. If a xenograft valve were im- 
planted in this patient, there would be an approxi- 
mately 85% probability of requiring re-replacement 
before death. Beyond 60 years of age at operation, 
there appears to be no difference in the predicted 
probability of re-replacement before death in patients 
with xenograft valves compared with patients with 
cryopreserved allograft valves. Beyond the age of 40 
years at operation, the predicted probability of re- 
replacement before death for a patient who receives a
4°C stored allograft valve is higher than that for 
patients who receive xenograft or cryopreserved allo- 
graft valves. In this study, failure of cryopreserved 
allograft valves caused by mechanical and technical 
reasons was an important reason for re-replacement. 
Allograft valve failure is a complex interplay between 
mechanisms such as leaflet degeneration, geometric 
distortion, changing mechanical properties of the leaf- 
let tissue, and aortic root dilation. However, the cur- 
rent preference for the cylindrical or root replacement 
technique of allograft valve insertion as opposed to the 
subcoronary technique (the method most frequently 
used in this series) may reduce the probability of 
re-replacement bydecreasing geometric distortion and 
hence improving leaflet coaptation. The efficacy of this 
strategy will require testing by repeating this study in 
the future. 
Inferences 
1. Younger age at operation is a risk factor for 
re-replacement of xenograft, 4°C stored, and 
cryopreserved allograft valves and this effect is a 
result of the competing risk of death and re- 
replacement, as well as a biologic predisposition 
to leaflet failure. 
2. Competing risk analysis provides the actual prob- 
ability of requiring a re-replacement during the 
remainder of the patient's life after aortic valve 
replacement. This is different information from 
that provided by the Kaplan-Meier estimate, 
which reflects valve durability. 
3. In patients older than approximately 60 years at 
the time of aortic valve replacement, he proba- 
bility of re-replacement (for any reason) before 
. 
death is no different for xenografts and cryopre- 
served allograft valves. However, for patients 
younger than approximately 60 years, in terms of 
the probability of re-replacement before death, 
the cryopreserved allograft is superior to the 
xenograft and 4 ° C stored allograft valves. 
In patients older than approximately 40 years, the 
probability of re-replacement before death re- 
mains higher with the 4 ° C stored allograft valve 
than with the xenograft or cryopreserved allo- 
graft valves. 
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Appendixes 
Appendix A: Variables entered into the multivariate 
models 
Demographic variables. Age at operation; gender. 
CLINICAL VARIABLES. New York Heart Association 
functional class immediately before operation (class V 
refers to shock); preoperative symptoms (angina, heart 
failure, syncope); significant lung disease and significant 
renal dysfunction; significant hepatic dysfunction; left 
ventricular dysfunction and atrial fibrillation; complete 
heart block; and aortic valve physiologic features (aortic 
stenosis, aortic regurgitation, mixed lesion). 
Significant lung disease was defined as chronic limiting 
symptoms caused by lung disease with objective vidence 
on respiratory function tests, chest radiograph, and other 
tests. Significant renal dysfunction was defined as level of 
creatinine greater than or equal to 0.2 mmol/L or level of 
urea greater than or equal to 15 retool/L, or both condi- 
tions. Significant hepatic dysfunction was defined as bili- 
rubin level greater than or equal to 35 mmol/L. Left 
ventricular dysfunction was defined on the basis of echo- 
cardiogram, radionuclide scan, or left ventriculogram at
cardiac atheterization. Ejection fraction was categorized 
as follows: normal, greater than 0.54; mild, 0.37 to 0.54; 
moderate, 0.20 to 0.37; and severe, less than 0.20. Frac- 
tional shortening was categorized as follows: normal, 
greater than 30%; mild, 20% to 30%; moderate, 10% to 
20%; and severe, less than 10%. 
PATHOLOGIC VARIABLES. Presence of coronary artery dis- 
ease; aortic vaJ~ve pathologic ondition (rheumatic, alcare- 
ous aortic valve disease caused by a congenitally abnormal 
valve); calcareous aortic valve disease on a trileaflet valve; 
infective endocarditis, prosthetic valve dysfunction, aortic 
wall disease, or congenital valve disease (noncalcareous); 
and degree of left ventricular hypertrophy. 
Calcareous aortic valve disease in a trileaflet valve was 
considered senile degenerative disease. Aortic wall dis- 
ease was a pathologic ondition of the aortic wall, includ- 
ing the aortic root, that resulted in dilation or dissection. 
For patients with endocarditis on a prosthetic valve or an 
abnormal valve (such as a rheumatic native valve) the 
pathologic ondition was classified as endocarditis. The 
degree of left ventricular hypertrophy was defined as 
normal, mild, moderate, or severe (on the basis of the 
surgeon's intraoperative assessment). 
SURGICAL VARIABLES. Date of operation; surgeon; car- 
diopulmonary bypass time; crossclamp time; use of car- 
dioplegia; valve type; valve size; associated procedures; 
and completeness of revascularization for patients with 
coronary artery disease. 
Appendix B 
We let Sl(t;x) and fl(t;x) denote the survival function 
and probability density function, respectively, where t 
denotes the time to death after the initial valve replace- 
ment operation for a patient age x (months) at the time of 
this operation. That is, 
Sl(t;x ) = pr{T > t} = fl(u;x)du 
Appendix Table I 
;ti 13i 
Xenograft valves 
i = 1 -11.3747 0.0462 -0.0026 
(0.3847) (0.0026) (0.0005) 
i = 2 -4.7421 0.0206 0.0059 
(0.3035) (0.0026) (0.0007) 
Cryopreserved 
allograft 
valves 
i = 1 -10.6683 0.0297 0.0027 
(1.630) (0 .0048)  (0.0022) 
i = 2 -5.2656 -0.0020 -0.0034 
(1.1348) (0.0084) (0.0015) 
4 ° C stored allo- 
graft valves 
i = 1 -16.6628 0.0598 0.0037 
(3.1028) (0.0149) (0.0016) 
i = 2 -6.7309 0.0112 -0.0021 
(0.5609) (0.0030) (0.0007) 
where T is the random variable denoting time to death. 
Concerning the other event of re-replacement, we let 
S2(t;x) and f2(t;x) denote the survival function and prob- 
ability density function, respectively, for a patient age x at 
the time of initial operation, where t denotes the time to 
re-replacement in a hypothetical population for which 
there is no competing risk of death. 
The survival function Si(t;x) is modeled as 
Si(t;x) = exp[-e×ea~(e 13~t- 1)//3i] 
for i = 1, 2. The corresponding hazard function h i (t;x) is 
given by 
hi(t;x) = eXhoi(t) 
where 
hoi(t) - e ~ + t~t 
is the hazard function for the Gompertz distribution. This 
effect of the age x of the patient at the time of the initial 
operation is modeled additively on the log scale of the 
baseline hazard function, which is taken to be of Gomp- 
ertz form. 
The survival functions Sl(t;x ) and S2(t;x ) were fitted 
separately to the data, using the method of maximum 
likelihood where, in the estimation of the latter, a patient 
who died without a re-replacement was taken to be 
censored with respect o this event. The values of the 
parameter estimates are shown in Appendix Table I. 
The cumulative incidence function C2(t;x) is defined as 
C2(t;x) = flf2(t;x)Sl(t;x)dt 
It can be interpreted as the probability that a patient age 
x at the time of the initial operation will undergo a 
3 1 8 McGif f in  et al. 
Appendix Table II 
4 ° C stored Oyopreselved 
Valve allograft allograft Xenograft 
0-5 yr 2 175 203 
5-10 yr 9 46 501 
10-15 yr 13 74 156 
> 15 yr 70 4 0 
Total 94 299 950 
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re-replacement by time t afterward (and before the com- 
peting risk of death occurs). Thus the quantity 
~-~(x) = G(o: ;x)  
is the probability that a patient age x at the time of the 
initial operation will actually undergo a re-replacement 
before death. 
Because the original data were no longer readily 
accessible, confidence intervals could not be presented. 
